Emelie Gezelius

Lund, M, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Brief Report: Proposed Clinical Trial Guidelines Based on Clinicopathologic Heterogeneity of Metastatic Pulmonary Large Cell Neuroendocrine Carcinoma.

Brief Report: Proposed Clinical Trial Guidelines Based on Clinicopathologic Heterogeneity of Metastatic Pulmonary Large Cell Neuroendocrine Carcinoma.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 15, 2026

Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas.

Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 04, 2025

Protumoral lipid droplet-loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted.

Protumoral lipid droplet-loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted.

Journal: Science translational medicine

Published: October 30, 2024

Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report.

Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report.

Journal: Cancer chemotherapy and pharmacology

Published: July 28, 2024

Longitudinal Assessment of Circulating Tumor Cells and Outcome in Small Cell Lung Cancer: A Sub-Study of RASTEN-A Randomized Trial with Low Molecular Weight Heparin.

Longitudinal Assessment of Circulating Tumor Cells and Outcome in Small Cell Lung Cancer: A Sub-Study of RASTEN-A Randomized Trial with Low Molecular Weight Heparin.

Journal: Cancers

Published: March 14, 2023

Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN).

Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN).

Journal: Cancers

Published: February 09, 2022

Biomarkers of venous thromboembolism in cancer: a silent echo from local events?

Biomarkers of venous thromboembolism in cancer: a silent echo from local events?

Journal: Biomarkers in medicine

Published: May 30, 2019

Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN).

Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN).

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 04, 2019

Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin.

Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin.

Journal: PloS one

Published: July 10, 2018

Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial.

Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 07, 2017

Showing 1-10 of 10

Last Updated: 09/26/2026